MGNX
Price
$1.73
Change
-$0.04 (-2.26%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
111.87M
70 days until earnings call
PGEN
Price
$4.78
Change
+$0.27 (+5.99%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
1.34B
71 days until earnings call
Interact to see
Advertisement

MGNX vs PGEN

Header iconMGNX vs PGEN Comparison
Open Charts MGNX vs PGENBanner chart's image
MacroGenics
Price$1.73
Change-$0.04 (-2.26%)
Volume$5.49K
Capitalization111.87M
Precigen
Price$4.78
Change+$0.27 (+5.99%)
Volume$303.45K
Capitalization1.34B
MGNX vs PGEN Comparison Chart in %
Loading...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MGNX vs. PGEN commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGNX is a Hold and PGEN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (MGNX: $1.77 vs. PGEN: $4.51)
Brand notoriety: MGNX and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MGNX: 97% vs. PGEN: 101%
Market capitalization -- MGNX: $111.87M vs. PGEN: $1.34B
MGNX [@Biotechnology] is valued at $111.87M. PGEN’s [@Biotechnology] market capitalization is $1.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MGNX’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • MGNX’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, PGEN is a better buy in the long-term than MGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MGNX’s TA Score shows that 3 TA indicator(s) are bullish while PGEN’s TA Score has 4 bullish TA indicator(s).

  • MGNX’s TA Score: 3 bullish, 4 bearish.
  • PGEN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than MGNX.

Price Growth

MGNX (@Biotechnology) experienced а +4.73% price change this week, while PGEN (@Biotechnology) price change was +7.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

MGNX is expected to report earnings on Nov 11, 2025.

PGEN is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PGEN($1.34B) has a higher market cap than MGNX($112M). PGEN YTD gains are higher at: 302.679 vs. MGNX (-45.538). MGNX has higher annual earnings (EBITDA): -26.91M vs. PGEN (-121.98M). MGNX has more cash in the bank: 176M vs. PGEN (59.8M). PGEN has less debt than MGNX: PGEN (5.15M) vs MGNX (37.2M). MGNX has higher revenues than PGEN: MGNX (164M) vs PGEN (4.34M).
MGNXPGENMGNX / PGEN
Capitalization112M1.34B8%
EBITDA-26.91M-121.98M22%
Gain YTD-45.538302.679-15%
P/E RatioN/AN/A-
Revenue164M4.34M3,779%
Total Cash176M59.8M294%
Total Debt37.2M5.15M722%
FUNDAMENTALS RATINGS
MGNX vs PGEN: Fundamental Ratings
MGNX
PGEN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5534
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (73) in the null industry is in the same range as MGNX (79) in the Biotechnology industry. This means that PGEN’s stock grew similarly to MGNX’s over the last 12 months.

PGEN's Profit vs Risk Rating (98) in the null industry is in the same range as MGNX (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to MGNX’s over the last 12 months.

MGNX's SMR Rating (98) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that MGNX’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (34) in the null industry is in the same range as MGNX (55) in the Biotechnology industry. This means that PGEN’s stock grew similarly to MGNX’s over the last 12 months.

MGNX's P/E Growth Rating (95) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that MGNX’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MGNXPGEN
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
85%
MACD
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 5 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 5 days ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 5 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
90%
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTUAX61.500.34
+0.56%
Fidelity Advisor Telecommunications A
PRISX48.740.04
+0.08%
T. Rowe Price Financial Services
CLREX55.63-0.29
-0.52%
Columbia Balanced Inst2
FCGIX20.80-0.13
-0.62%
NYLI PineStone Global Equity Class I
PCLCX19.31-0.18
-0.92%
PACE Large Co Growth Equity P

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with XENE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-0.88%
XENE - PGEN
39%
Loosely correlated
+0.28%
ZNTL - PGEN
38%
Loosely correlated
-3.98%
KPTI - PGEN
38%
Loosely correlated
-7.42%
MGNX - PGEN
38%
Loosely correlated
+4.12%
IMNM - PGEN
38%
Loosely correlated
-3.94%
More